<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263665</url>
  </required_header>
  <id_info>
    <org_study_id>VBL 10-04</org_study_id>
    <nct_id>NCT01263665</nct_id>
  </id_info>
  <brief_title>Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis</brief_title>
  <official_title>Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface to Treat de Novo and/or Restenotic Lesions of the Superficial Femoral Artery (SFA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and performance of the 25 cm GORE®
      VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used in the Superficial Femoral
      Artery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Completion of the Assigned Treatment</measure>
    <time_frame>Evaluated immediately after the index procedure</time_frame>
    <description>Successful completion of the assigned treatment and postdeployment
&gt; stent length (of the first deployed 25 cm GORE
&gt; VIABAHN Endoprosthesis with PROPATEN Bioactive Surface)
&gt; being within 10% of pre-deployment stent length.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device-related and Procedure-related Serious Adverse Events (SAEs) Within 30 Days of the Index Procedure</measure>
    <time_frame>30 Days post-procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>25cm Gore VIABAHN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>25 cm GORE® VIABAHN®</intervention_name>
    <description>25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).</description>
    <arm_group_label>25cm Gore VIABAHN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lifestyle-limiting claudication or rest pain (meeting angiographic entry criteria)
             affecting a lower extremity (Rutherford Categories 2-4).

          -  A written informed consent form, which has been reviewed and approved by the Ethics
             Committee, has been read, understood and signed by the subject (or their legally
             authorized representative).

          -  At least 21 years of age.

          -  Noninvasive lower extremity arterial studies (ankle-brachial index, ABI) prior to
             (within 45 days) or at the time of the study procedure demonstrating a resting
             ankle-brachial index (ABI) ≤ 0.9 in the study limb. If ABI &gt; 0.9, patient is eligible
             for study if toe-brachial index (TBI) is ≤ 0.5.

          -  A staged ipsilateral vascular procedure was not completed less than 30-days prior to
             the study procedure. Resting ABIs were completed prior to the study procedure a
             minimum of 30-days after the staged vascular procedure.

          -  Vascular treatment on the non-study leg for bilateral claudication was not performed
             less than 30-days prior to study procedure. Resting ABIs on the study limb were
             completed prior to the study procedure a minimum of 30-days after treatment on the
             non-study leg.

          -  Male, infertile female, or female of child bearing potential practicing an acceptable
             method of birth control with a negative pregnancy test within 7-days prior to study
             procedure.

          -  Projected life expectancy of greater than three years.

          -  The ability to comply with protocol follow-up requirements and required testing.

          -  Angiographic and Lesion Requirements (assessed intraoperatively):

          -  Lesion length of 20-35 cm located in the region beginning 1 cm below origin of the
             profunda femoris artery and ending 1 cm above the origin of the intercondylar fossa.

          -  De novo, post-percutaneous transluminal angioplasty (PTA), or post-atherectomy
             stenosis (&gt; 50% at some point within the lesion by visual estimate) or occlusion of
             native SFA.

          -  Origin and proximal 1 cm of SFA are patent.

          -  Popliteal artery is patent from 1 cm above the origin of the intercondylar fossa
             distal to the radiographic knee joint.

          -  Reference vessel diameter of 4.0 - 7.5 mm in proximal and distal treatment segments
             within the SFA.

          -  Angiographic evidence of at least one patent tibial artery to the ankle that does not
             require intervention.

          -  Guidewire has successfully traversed lesion and is within the true lumen of the distal
             vessel.

        Exclusion Criteria:

          -  Untreated flow-limiting aortoiliac occlusive disease.

          -  Any previous open surgical procedure in the target vessel or previous stent placement
             in the target vessel.

          -  Prior angioplasty on the target lesion performed less than 30 days prior to the study
             procedure (unless performed at time of the study procedure).

          -  Prior atherectomy on the target lesion performed less than 6 months prior to the study
             procedure (unless performed at time of the study procedure).

          -  Any previous treatment of the target vessel with a drug-eluting balloon.

          -  Femoral artery or popliteal artery aneurysm.

          -  Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease,
             vasculitis).

          -  Tibial artery disease requiring treatment.

          -  Prior ipsilateral femoral artery bypass.

          -  Severe medical comorbidities (untreated coronary artery disease, congestive heart
             failure, severe chronic obstructive pulmonary disease, metastatic malignancy,
             dementia, etc.) or other medical condition that would preclude post-procedural
             ambulation.

          -  Popliteal artery vascular access at any time during procedure.

          -  Antegrade and retrograde vascular access on the same common femoral artery at the time
             of the SFA intervention.

          -  Major distal amputation (above the transmetatarsal) in the study or non-study limb.

          -  Septicemia.

          -  Any previously known coagulation disorder, including hypercoagulability.

          -  Morbid obesity or operative scarring that precludes percutaneous approach (physician's
             discretion).

          -  Contraindication to anticoagulation or antiplatelet therapy.

          -  Known allergies to stent/stent-graft components, including heparin sensitivity,
             allergy, or previous incidence of heparin-induced thrombocytopenia (HIT) type II.

          -  History of prior life-threatening reaction to contrast agent.

          -  Currently participating in another clinical research trial, unless approved by W. L.
             Gore &amp; Associates in advance of study enrollment.

          -  Subject has one limb currently enrolled in the study.

          -  Current peritoneal or hemodialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Zeller, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Bad Krozingen</affiliation>
  </overall_official>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <results_first_submitted>January 13, 2014</results_first_submitted>
  <results_first_submitted_qc>January 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2014</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent-graft</keyword>
  <keyword>superficial femoral artery</keyword>
  <keyword>SFA</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>PAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>25 cm Length GORE® VIABAHN® Endoprosthesis With PROPATEN Bioac</title>
          <description>25 cm length GORE® VIABAHN® Endoprosthesis with
&gt; PROPATEN Bioactive Surface Subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Amputation above the ankle</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgical Bypass</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with de novo and/or restenotic lesions (post PTA) of the SFA, with a total lesion length of ≥ 20 cm based on visual estimate</population>
      <group_list>
        <group group_id="B1">
          <title>Investigational Arm</title>
          <description>25 cm length GORE® VIABAHN® Endoprosthesis with &gt; PROPATEN Bioactive Surface Subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" lower_limit="44.7" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Completion of the Assigned Treatment</title>
        <description>Successful completion of the assigned treatment and postdeployment &gt; stent length (of the first deployed 25 cm GORE &gt; VIABAHN Endoprosthesis with PROPATEN Bioactive Surface) &gt; being within 10% of pre-deployment stent length.</description>
        <time_frame>Evaluated immediately after the index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 cm Length GORE® VIABAHN® Endoprosthesis With PROPATEN Bioac</title>
            <description>25 cm length GORE® VIABAHN® Endoprosthesis with &gt; PROPATEN Bioactive Surface Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Completion of the Assigned Treatment</title>
          <description>Successful completion of the assigned treatment and postdeployment &gt; stent length (of the first deployed 25 cm GORE &gt; VIABAHN Endoprosthesis with PROPATEN Bioactive Surface) &gt; being within 10% of pre-deployment stent length.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Device-related and Procedure-related Serious Adverse Events (SAEs) Within 30 Days of the Index Procedure</title>
        <time_frame>30 Days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25 cm Length GORE® VIABAHN® Endoprosthesis With PROPATEN Bioac</title>
            <description>25 cm length GORE® VIABAHN® Endoprosthesis with &gt; PROPATEN Bioactive Surface Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Device-related and Procedure-related Serious Adverse Events (SAEs) Within 30 Days of the Index Procedure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Total through 2 years, data pulled as of 10Oct2014</time_frame>
      <group_list>
        <group group_id="E1">
          <title>25 cm GORE VIABAHN</title>
          <description>25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Before the single-center publication is submitted or presented, the &gt; Investigator will provide a copy to the Sponsor and allow the Sponsor 30 days to review and &gt; comment. The Sponsor will review the publication for data accuracy only and not the &gt; conclusions or interpretations. If the Sponsor requests, the publication will be delayed an &gt; additional ninety (90) days, to allow Sponsor to ensure the protection of inventions or other &gt; property of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keli Sapp</name_or_title>
      <organization>W.L. Gore &amp; Associates</organization>
      <phone>9288643964</phone>
      <email>kesapp@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

